Von Hippel-Lindau Disease synonyms

Von Hippel-Lindau disease, commonly abbreviated as VHL, is a rare genetic disorder characterized by the growth of tumors and cysts in various parts of the body. While it is almost universally referred to as Von Hippel-Lindau disease in modern medical literature, it was historically known as angiomatosis retinae or cerebelloretinal hemangioblastomatosis.

What are the historical and alternative names for Von Hippel-Lindau disease?

In medical history, Von Hippel-Lindau disease has been identified by several descriptive names that reflect the clinical findings of the researchers who first characterized it. These include Lindau disease, von Hippel disease, and the combined eponym von Hippel-Lindau syndrome. Older literature may occasionally refer to the condition as cerebelloretinal angiomatosis or retinocerebellar angiomatosis, terms that focus on the hallmark hemangioblastomas found in the retina and the central nervous system. Understanding these synonyms is vital for patients reviewing older medical records or conducting historical literature searches, as these terms are now considered obsolete in clinical practice.

Why does Von Hippel-Lindau disease have multiple names?

The nomenclature of Von Hippel-Lindau disease reflects the evolution of our understanding of the condition. In 1904, ophthalmologist Eugen von Hippel described the retinal angiomas, while in 1926, pathologist Arvid Lindau identified the association between these retinal lesions and cerebellar hemangioblastomas. Over time, the medical community recognized that these findings were manifestations of a single, multisystem genetic syndrome. Today, the unified name Von Hippel-Lindau disease is used to reflect the systemic nature of the VHL gene mutation, which affects multiple organ systems rather than just the eyes or brain.

What are the official medical classifications for this condition?

Standardized medical coding systems provide a consistent way to track Von Hippel-Lindau disease across global health systems. These identifiers are essential for insurance, clinical research, and patient registry documentation:

• OMIM (Online Mendelian Inheritance in Man): #193300


• Orphanet: ORPHA892


• ICD-10: Q85.8 (Other phakomatoses, not elsewhere classified)


• ICD-11: LD2H.0 (Von Hippel-Lindau syndrome)

Which name is preferred by medical professionals today?

While various historical terms exist, Von Hippel-Lindau disease is the universally accepted terminology used by clinical geneticists, oncologists, and neurosurgeons. The abbreviation "VHL" is also widely utilized in both clinical settings and patient advocacy circles, including within the DiseaseMaps.org community, where over 100 members currently connect and share experiences related to this diagnosis. Using the standard eponym ensures clarity during multidisciplinary care, which is essential for managing the diverse tumor risks associated with the VHL gene mutation.

Next steps

• Consult with a clinical geneticist to confirm your diagnosis and discuss the implications for family members.


• Request a referral to a VHL Comprehensive Clinical Care Center for specialized, multidisciplinary surveillance.


• Join the DiseaseMaps.org community to connect with other patients and caregivers navigating the complexities of Von Hippel-Lindau disease.


• Register with the VHL Alliance to access updated clinical guidelines and information on ongoing research trials.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD): Von Hippel-Lindau disease.


• Orphanet: Von Hippel-Lindau disease (ORPHA892).


• OMIM (Online Mendelian Inheritance in Man): Entry #193300.


• VHL Alliance: Official patient advocacy and clinical resource organization.